CD68 and urinary bladder cancer: Moreover, the pooled results based on meta-analysis also indicated that there was no significant association between CD68+ TAMs and PFS in bladder cancer patients (HR = 1.19, 95% CI = 0.70~1.68) (Figure 2C).